Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Research Article

Comparison of the Efficacy of Repaglinide Versus the Combination of Mitiglinide and Voglibose on Glycemic Variability in Japanese Patients with Type 2 Diabetes

Author(s): Hiroshi Okada*, Muhei Tanaka, Goji Hasegawa, Hanako Nakajima, Mayuko Kadono, Yuki Okada, Atsuhiro Hirata, Hirokazu Oyamada, Tetsuro Yamane and Michiaki Fukui

Volume 25, Issue 43, 2019

Page: [4600 - 4605] Pages: 6

DOI: 10.2174/1381612825666190920124853

Price: $65

Abstract

Background: Glycemic variability is a risk factor for total death and cardiovascular events. There are no obvious guidelines for the direct treatment of glycemic variability, but it can be improved with the treatment of postprandial hyperglycemia.

Objective: We compared the effect of repaglinide versus the combination of mitiglinide and voglibose, used to improve postprandial hyperglycemia, on glycemic variability in Japanese patients with type 2 diabetes.

Methods: We performed an open-label randomized cross-over trial between April 2016 and April 2018. Patients with type 2 diabetes who were admitted to our hospital were enrolled in our study (n = 12). Glycemic variability. was assessed using a continuous glucose monitoring system.

Results: The average glucose level of the repaglinide phase (146.1 ± 20.7 mg/dl) and the combination of mitiglinide and voglibose phase (132.3 ± 19.8 mg/dl) were similar (P = 0.10). The standard division (P = 0.0005), coefficient of variation (P = 0.006), and mean amplitude of glycemic excursion (P = 0.002) of glucose were lower in the combination of mitiglinide and voglibose phase than in the repaglinide phase.

Conclusion: Treatment with the combination of mitiglinide and voglibose might be more effective than repaglinide for the improvement of glycemic variability.

Keywords: Glycemic variability, type 2 diabetes, postprandial hyperglycemia, repaglinide, mitiglinide, voglibose.

« Previous Next »
[1]
Suh S, Joung JY, Jin SM, et al. Strong correlation between glycaemic variability and total glucose exposure in type 2 diabetes is limited to subjects with satisfactory glycaemic control. Diabetes Metab 2014; 40(4): 272-7.
[http://dx.doi.org/10.1016/j.diabet.2014.01.006] [PMID: 24630733]
[2]
Su G, Mi S, Tao H, et al. Association of glycemic variability and the presence and severity of coronary artery disease in patients with type 2 diabetes. Cardiovasc Diabetol 2011; 10: 19.
[http://dx.doi.org/10.1186/1475-2840-10-19] [PMID: 21349201]
[3]
The DECODE study group. European diabetes epidemiology group Glucose tolerance and mortality: comparison of WHO and american diabetes association diagnostic criteria. Diabetes epidemiology: collaborative analysis of diagnostic criteria in europe. Lancet 1999; 354(9179): 617-21.
[http://dx.doi.org/10.1016/S0140-6736(98)12131-1] [PMID: 10466661]
[4]
The DECODE study group. European diabetes epidemiology group. Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161(3): 397-405.
[http://dx.doi.org/10.1001/archinte.161.3.397] [PMID: 11176766]
[5]
Avogaro A. Postprandial glucose: marker or risk factor? Diabetes Care 2011; 34(10): 2333-5.
[http://dx.doi.org/10.2337/dc11-1442] [PMID: 21949226]
[6]
Seaquist ER, Miller ME, Bonds DE, et al. The impact of frequent and unrecognized hypoglycemia on mortality in the ACCORD study. Diabetes Care 2012; 35(2): 409-14.
[http://dx.doi.org/10.2337/dc11-0996] [PMID: 22179956]
[7]
Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002; 359(9323): 2072-7.
[http://dx.doi.org/10.1016/S0140-6736(02)08905-5] [PMID: 12086760]
[8]
Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004; 25(1): 10-6.
[http://dx.doi.org/10.1016/S0195-668X(03)00468-8] [PMID: 14683737]
[9]
Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004; 27(6): 1265-70.
[http://dx.doi.org/10.2337/diacare.27.6.1265] [PMID: 15161773]
[10]
Kawamori R, Kaku K, Hanafusa T, Kashiwabara D, Kageyama S, Hotta N. Efficacy and safety of repaglinide vs nateglinide for treatment of japanese patients with type 2 diabetes mellitus. J Diabetes Investig 2012; 3(3): 302-8.
[http://dx.doi.org/10.1111/j.2040-1124.2011.00188.x] [PMID: 24843581]
[11]
Katsuno T, Watanabe N, Nagai E, et al. Comparison of with voglibose efficacy of concomitant administration of mitiglinide 2 diabetes and double dose of mitiglinide in patients with type mellitus. J Diabetes Investig 2011; 2(3): 204-9.
[http://dx.doi.org/10.1111/j.2040-1124.2010.00082.x] [PMID: 24843485]
[12]
Yamazaki M, Hasegawa G, Majima S, et al. Effect of repaglinide versus glimepiride on daily blood glucose variability and changes in blood inflammatory and oxidative stress markers. Diabetol Metab Syndr 2014; 6: 54.
[http://dx.doi.org/10.1186/1758-5996-6-54] [PMID: 24843385]
[13]
Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26(Suppl. 1): S5-S20.
[http://dx.doi.org/10.2337/diacare.26.2007.S5] [PMID: 12502614]
[14]
Service FJ, Molnar GD, Rosevear JW, Ackerman E, Gatewood LC, Taylor WF. Mean amplitude of glycemic excursions, a measure of diabetic instability. Diabetes 1970; 19(9): 644-55.
[http://dx.doi.org/10.2337/diab.19.9.644] [PMID: 5469118]
[15]
Beck RW, Connor CG, Mullen DM, Wesley DM, Bergenstal RM. The fallacy of average: how using HbA1c alone to assess glycemic control can be misleading. Diabetes Care 2017; 40(8): 994-9.
[http://dx.doi.org/10.2337/dc17-0636] [PMID: 28733374]
[16]
Fujimoto K, Shibayama Y, Yamaguchi E, Honjo S, Hamasaki A, Hamamoto Y. Glucose excursions and hypoglycemia in patients with type 2 diabetes treated with mitiglinide/voglibose versus glimepiride: a randomized cross-over trial. J Diabetes 2018; 10(8): 675-82.
[http://dx.doi.org/10.1111/1753-0407.12658] [PMID: 29493100]
[17]
Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295(14): 1681-7.
[http://dx.doi.org/10.1001/jama.295.14.1681] [PMID: 16609090]
[18]
Williams SB, Goldfine AB, Timimi FK, et al. Acute hyperglycemia attenuates endothelium-dependent vasodilation in humans in vivo. Circulation 1998; 97(17): 1695-701.
[http://dx.doi.org/10.1161/01.CIR.97.17.1695] [PMID: 9591763]
[19]
Esposito K, Ciotola M, Carleo D, et al. Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes. J Clin Endocrinol Metab 2008; 93(4): 1345-50.
[http://dx.doi.org/10.1210/jc.2007-2000] [PMID: 18198229]
[20]
Torimoto K, Okada Y, Mori H, Tanaka Y. Low levels of 1,5-anhydro-D-glucitol are associated with vascular endothelial dysfunction in type 2 diabetes. Cardiovasc Diabetol 2014; 13: 99.
[http://dx.doi.org/10.1186/1475-2840-13-99] [PMID: 24924149]
[21]
Chen XM, Zhang Y, Shen XP, et al. Correlation between glucose fluctuations and carotid intima-media thickness in type 2 diabetes. Diabetes Res Clin Pract 2010; 90(1): 95-9.
[http://dx.doi.org/10.1016/j.diabres.2010.05.004] [PMID: 20605247]
[22]
Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A. Abnormal glucose metabolism and pancreatic cancer mortality. JAMA 2000; 283(19): 2552-8.
[http://dx.doi.org/10.1001/jama.283.19.2552] [PMID: 10815119]
[23]
Shiraiwa T, Kaneto H, Miyatsuka T, et al. Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. Biochem Biophys Res Commun 2005; 336(1): 339-45.
[http://dx.doi.org/10.1016/j.bbrc.2005.08.158] [PMID: 16140262]
[24]
Abbatecola AM, Rizzo MR, Barbieri M, et al. Postprandial plasma glucose excursions and cognitive functioning in aged type 2 diabetics. Neurology 2006; 67(2): 235-40.
[http://dx.doi.org/10.1212/01.wnl.0000224760.22802.e8] [PMID: 16864814]
[25]
Assaloni R, Da Ros R, Quagliaro L, et al. Effects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patients. Diabetologia 2005; 48(9): 1919-24.
[http://dx.doi.org/10.1007/s00125-005-1849-5] [PMID: 16007412]
[26]
Kitasato L, Tojo T, Hatakeyama Y, Kameda R, Hashikata T, Yamaoka-Tojo M. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide. Cardiovasc Diabetol 2012; 11: 79.
[http://dx.doi.org/10.1186/1475-2840-11-79] [PMID: 22748110]
[27]
Goto A, Arah OA, Goto M, Terauchi Y, Noda M. Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis. BMJ 2013; 347: f4533.
[http://dx.doi.org/10.1136/bmj.f4533] [PMID: 23900314]
[28]
Whitmer RA, Karter AJ, Yaffe K, Quesenberry CP Jr, Selby JV. Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 2009; 301(15): 1565-72.
[http://dx.doi.org/10.1001/jama.2009.460] [PMID: 19366776]
[29]
Abe M, Okada K, Maruyama T, Maruyama N, Matsumoto K. Efficacy and safety of mitiglinide in diabetic patients on maintenance hemodialysis. Endocr J 2010; 57(7): 579-86.
[http://dx.doi.org/10.1507/endocrj.K09E-318] [PMID: 20467165]
[30]
Ono Y, Kameda H, Cho KY. Mitiglinide/voglibose fixed-dose combination improves postprandial glycemic excursions in Japanese patients with type 2 diabetes mellitus. Expert Opin Pharmacother 2013; 14(4): 361-70.
[http://dx.doi.org/10.1517/14656566.2013.770839] [PMID: 23414242]
[31]
Kodama K, Tojjar D, Yamada S, Toda K, Patel CJ, Butte AJ. Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis. Diabetes Care 2013; 36(6): 1789-96.
[http://dx.doi.org/10.2337/dc12-1235] [PMID: 23704681]
[32]
Fukushima M, Suzuki H, Seino Y. Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes. Diabetes Res Clin Pract 2004; 66(Suppl. 1): S37-43.
[http://dx.doi.org/10.1016/j.diabres.2003.11.024] [PMID: 15563978]
[33]
Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 2003; 26(3): 881-5.
[http://dx.doi.org/10.2337/diacare.26.3.881] [PMID: 12610053]
[34]
McMurray JJ, Holman RR, Haffner SM, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med 2010; 362(16): 1477-90.
[http://dx.doi.org/10.1056/NEJMoa1001121] [PMID: 20228403]

Rights & Permissions Print Cite
Article Metrics
16
© 2024 Bentham Science Publishers | Privacy Policy